Home Newsfeeds Processa Says Successfully Identifies Next Generation Capecitabine Dosage Regimens For Phase 2B Trial

Processa Says Successfully Identifies Next Generation Capecitabine Dosage Regimens For Phase 2B Trial

Next Generation Capecitabine (NGC) Dosage Regimens Have Been Identified In The Ongoing Phase

November 1, 2022

1 minute read

Next Generation Capecitabine (NGC) Dosage Regimens Have Been Identified In The Ongoing Phase 1B Trial With Potentially Better Safety And Efficacy Profiles Than Existing Chemotherapy

Canaccord Genuity Maintains Hold on Stryker, Raises Price Target to $250

By Benzinga Newsdesk

February 1, 9:41 AM

Canaccord Genuity analyst Kyle Rose maintains Stryker (NYSE:SYK) with a Hold and raises the price target from $220 to $250.

SYK

Here’s How Much You Would Have Made Owning ONEOK Stock In The Last 20 Years

By Benzinga Insights

August 3, 1:46 PM

ONEOK (NYSE:OKE) has outperformed the market over the past 20 years by 1.52% on an annualized basis producing an average annual return of 9.42%. Currently, ONEOK has a market capitalization of $26.27 billion.

OKE

Additional Interim Data From Phase I/II/III CAMPSIITE Trial Of REGENXBIO’s RGX-121 For The Treatment Of MPS II (Hunter Syndrome) Presented At 19th Annual WORLDSymposium

By Happy Mohamed

February 22, 4:19 PM

RGX-121, a potential one-time gene therapy for the treatment of MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels Additional data from patients in Cohort 3 using pivotal program

RGNX

KB Home’s Q3 Earnings Beat Expectations, But Analysts Cautious On Q4 Margins

By Priya Nigam

September 21, 12:53 PM

Shares of KB Home (NYSE: KBH) came under pressure in early trading on Tuesday, after the company reported a decline in sales for its fiscal third quarter

KBH

Processa Says Successfully Identifies Next Generation Capecitabine Dosage Regimens For Phase 2B Trial

Related Posts

Canaccord Genuity Maintains Hold on Stryker, Raises Price Target to $250

Here’s How Much You Would Have Made Owning ONEOK Stock In The Last 20 Years

Additional Interim Data From Phase I/II/III CAMPSIITE Trial Of REGENXBIO’s RGX-121 For The Treatment Of MPS II (Hunter Syndrome) Presented At 19th Annual WORLDSymposium

KB Home’s Q3 Earnings Beat Expectations, But Analysts Cautious On Q4 Margins